All In Biotech

Drug Trial Radar · NCT01252732

Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection

A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO II)

Last checked: Nov 19, 2026Latest source record: May 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,019 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,019

Actual

Start

Dec 2010

Primary completion

Jun 2013

Study completion Jun 2013

Sponsor

Lead sponsor
Melinta Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 3, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 3 trial is to evaluate the efficacy, safety, and tolerability of oritavancin in ABSSSIs, including those caused by MRSA and to evaluate the potential economic benefit of oritavancin administered as a single 1200 mg IV dose.

Conditions

  • Wound Infection
  • Abscess
  • Systemic Inflammation
  • Cellulitis

Interventions

  • Single-Dose IV Oritavancin DiphosphateDrug

    Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.

  • IV VancomycinDrug

    Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Early Clinical ResponseTime frame: 48-72 hours after the initation of study therapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sharp Grossmont Hospital

    La Mesa, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.